Prominent publications by Jaime J Kulisevsky

KOL Index score: 16920

Background: Dopamine agonists have a well established role in the treatment of Parkinson’s disease. The choice of a particular dopamine agonist requires assessing the benefit-risk balance of each available medication.Objective: The present study evaluated the tolerability and safety of ropinirole against those of other dopamine agonists (bromocriptine, cabergoline, pramipexole, rotigotine, pergolide) and placebo in monotherapy and adjuvant therapy with levodopa in the treatment of ...

Also Ranks for: Dopamine Agonists |  placebo ropinirole |  pramipexole rotigotine |  levodopa treatment |  tolerability safety
KOL Index score: 14025

BACKGROUND: Dementia in Parkinson disease (PD) causes nursing home placement, caregiver distress, higher health care burden, and increased mortality.

OBJECTIVE: To determine whether the microtubule-associated protein tau (MAPT) H1 haplotype and MAPT subhaplotypes play a role in the risk of PD and Parkinson disease-dementia (PDD) complex.

DESIGN: Case-control genetic analysis.

SETTING: Movement Disorders and Memory Units, Hospital de Sant Pau, Barcelona, Spain.

PARTICIPANTS: Two hundred ...

Also Ranks for: Parkinson Disease |  mapt haplotype |  patients dementia |  movement disorders |  lewy body
KOL Index score: 13609

This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS-UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve ...

Also Ranks for: Clinimetric Testing |  movement disorder society |  rating scale |  unified parkinson |  mdsupdrs updrs
KOL Index score: 12466

BACKGROUND: Cholinergic deficits are prominent in patients who have dementia associated with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such patients.

METHODS: Patients in whom mild-to-moderate dementia developed at least 2 years after they received a clinical diagnosis of Parkinson's disease were randomly assigned to receive placebo or 3 to 12 mg of rivastigmine per day for 24 weeks. Primary efficacy variables were the scores ...

Also Ranks for: Patients Rivastigmine |  dementia parkinsons disease |  24 weeks |  nausea vomiting |  cholinergic deficits
KOL Index score: 12072

BACKGROUND: Parkinson's disease (PD) is a progressive neurodegenerative disorder causing motor and non-motor symptoms that can affect independence, social adjustment and the quality of life (QoL) of both patients and caregivers. Studies designed to find diagnostic and/or progression biomarkers of PD are needed. We describe here the study protocol of COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), an integral PD project based on four aspects/concepts: 1) PD as ...

Also Ranks for: Serum Biomarkers |  parkinson disease |  genetic studies |  patients caregivers |  global –clinical evaluations
KOL Index score: 11734

BACKGROUND/AIMS: Neurodegenerative disorders (ND) have a major impact on quality of life (QoL) and place a substantial burden on patients, their families and carers; they are the second leading cause of disability. The objective of this study was to examine QoL in persons with ND.

METHODS: A battery of subjective assessments was used, including the World Health Organization Quality of Life Questionnaire (WHOQOL-BREF) and the World Health Organization Quality of Life - Disability ...

Also Ranks for: Quality Life |  whoqolbref whoqoldis |  psychometric properties |  health organization |  subjective assessments
KOL Index score: 11169

Importance: Although levodopa remains the most effective oral pharmacotherapy for Parkinson disease (PD), its use is often limited by wearing off effect and dyskinesias. Management of such complications continues to be a significant challenge.

Objective: To investigate the efficacy and safety of safinamide (an oral aminoamide derivative with dopaminergic and nondopaminergic actions) in levodopa-treated patients with motor fluctuations.

Design, Setting, and Participants: From March 5, ...

Also Ranks for: Motor Fluctuations |  parkinson disease |  troublesome dyskinesia |  efficacy safety |  patients safinamide
KOL Index score: 10833

OBJECTIVE: To confirm that performance in verbal learning and memory test (Rey's Auditory Verbal Learning Test-RAVLT) is a helpful early neuropsychological marker of dementia of Alzheimer's type (DAT).

METHODS: RAVLT was administered as part of a more extensive neuropsychological battery at baseline evaluation in 116 unselected patients referred by subjective memory complaints (SMC). Patients were followed longitudinally for 2 years (average interval of 27.7+/-4 months). Seventy patients ...

Also Ranks for: Normal Aging |  differential diagnosis |  verbal learning |  mild cognitive |  smc patients
KOL Index score: 10209

We present a clinimetric assessment of the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The MDS-UDPRS Task Force revised and expanded the UPDRS using recommendations from a published critique. The MDS-UPDRS has four parts, namely, I: Non-motor Experiences of Daily Living; II: Motor Experiences of Daily Living; III: Motor Examination; IV: Motor Complications. Twenty questions are completed by the patient/caregiver. ...

Also Ranks for: Movement Disorder |  disease rating |  clinimetric testing |  mdsupdrs parts |  unified parkinson
KOL Index score: 10127

Patients with dementia of Alzheimer's type (DAT) show severe impairment in recognizing famous people. The aim of the current study was to investigate if this well-known memory impairment of famous faces is already present in the preclinical phase of DAT and if the famous faces test can help to differentiate patients with mild cognitive impairment (MCI) who progress to dementia and those who do not. We compared baseline performance in a task of famous face identification in a sample of ...

Also Ranks for: Famous People |  semantic knowledge |  mild cognitive impairment |  patients mci |  alzheimer disease
KOL Index score: 10112

Cognitive defects associated with cortical pathology may be a marker of dementia in Parkinson's disease (PD). There is a need to improve the diagnostic criteria of PD dementia (PDD) and to clarify the cognitive impairment patterns associated with PD. Current neuropsychological batteries designed for PD are focused on fronto-subcortical deficits but are not sensitive for cortical dysfunction. We developed a new scale, the Parkinson's Disease-Cognitive Rating Scale (PD-CRS), that was ...

Also Ranks for: Cognitive Scale |  dementia pdd |  illness surveys |  pdcrs items |  verbal fluency
KOL Index score: 10047

BACKGROUND: In studies of mild cognitive impairment (MCI) in Parkinson disease (PD), patients without dementia have reported variable prevalences and profiles of MCI, likely to be due to methodologic differences between the studies.

OBJECTIVE: The objective of this study was to determine frequency and the profile of MCI in a large, multicenter cohort of well-defined patients with PD using a standardized analytic method and a common definition of MCI.

METHODS: A total of 1,346 patients ...

Also Ranks for: Parkinson Disease |  patients mci |  mild cognitive impairment |  cognitive domains |  verbal memory
KOL Index score: 9882

BACKGROUND: Dementia is a frequent and devastating complication in Parkinson's disease (PD). There is an intensive search for biomarkers that may predict the progression from normal cognition (PD-NC) to dementia (PDD) in PD. Mild cognitive impairment in PD (PD-MCI) seems to represent a transitional state between PD-NC and PDD. Few studies have explored the structural changes that differentiate PD-NC from PD-MCI and PDD patients.

OBJECTIVES AND METHODS: We aimed to analyze changes in ...

Also Ranks for: Cortical Thinning |  dementia pdd |  parkinson disease |  pdnc pdmci |  cognitive decline
KOL Index score: 9575

There is controversy regarding the definition and characteristics of mild cognitive impairment in Parkinson's disease. The Movement Disorder Society commissioned a Task Force to critically evaluate the literature and determine the frequency and characteristics of Parkinson's disease-mild cognitive impairment and its association with dementia. A comprehensive PubMed literature review was conducted using systematic inclusion and exclusion criteria. A mean of 26.7% (range, 18.9%-38.2%) of ...

Also Ranks for: Task Force |  cognitive impairment |  disease mild |  neuropsychological tests |  nondemented patients

Key People For Parkinson Disease

Top KOLs in the world
Andrew **** ******
parkinsons disease progressive supranuclear motor fluctuations
Anthony ****** ****
parkinson disease movement disorders subthalamic nucleus
Werner * *****
parkinson disease multiple atrophy restless legs syndrome
Christopher * *****
parkinson disease movement disorders rating scales
Charles * ******
parkinson disease oxidative stress motor complications
Joseph * ********
movement disorders parkinson disease essential tremor

Jaime J Kulisevsky:Expert Impact

Concepts for whichJaime J Kulisevskyhas direct influence:Parkinson disease,  Parkinsons disease,  Cognitive impairment,  Minor hallucinations,  Essential tremor,  Coppadis cohort,  Mild cognitive impairment,  Neuropsychiatric symptoms.

Jaime J Kulisevsky:KOL impact

Concepts related to the work of other authors for whichfor which Jaime J Kulisevsky has influence:Parkinson disease,  Cognitive impairment,  Deep brain stimulation,  Motor symptoms,  Essential tremor,  Lewy bodies,  Movement disorders.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain | Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Mas Casanovas 90, 08041, Barcelona, Spain | Movement Disorders Unit, Ne